Fulminant Myocarditis in Patients With Autoimmune Disease That Requires Extracorporeal Membrane Oxygenation Support
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu kazuistiky, časopisecké články
PubMed
39279267
PubMed Central
PMC11403156
DOI
10.14503/thij-24-8431
PII: 503036
Knihovny.cz E-zdroje
- Klíčová slova
- autoimmunity, connective tissue diseases, extracorporeal membrane oxygenation, immunoglobulin G4-related disease, immunosuppression therapy, lupus erythematosus, systemic, myocarditis, polymyositis,
- MeSH
- autoimunitní nemoci diagnóza terapie imunologie komplikace MeSH
- biopsie MeSH
- IgG4 asociovaná nemoc diagnóza terapie komplikace MeSH
- kardiogenní šok terapie etiologie diagnóza MeSH
- lidé MeSH
- mimotělní membránová oxygenace * metody MeSH
- myokard patologie imunologie MeSH
- myokarditida * terapie diagnóza patofyziologie imunologie MeSH
- systémový lupus erythematodes komplikace diagnóza terapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
Myocarditis is a potentially life-threatening inflammatory disease of the myocardium, often resulting from infectious and immune-mediated responses. Clinical presentation in severe cases often results in a devastating illness requiring extracorporeal membrane oxygenation support as a result of cardiogenic shock. Although endomyocardial biopsy is still considered the gold standard for diagnosis, it often reveals nonspecific lymphocytic infiltration. Because the precise cause is usually unknown, the initial treatment typically involves immunosuppression and frequent assessment of myocardial contractility. This report presents 3 rare cases of autoimmune diseases (polymyositis, immunoglobulin G4-related disease, and systemic lupus erythematosus) that require extracorporeal membrane oxygenation support as a result of fulminant myocarditis, including their follow-up periods.
Department of Cardiology East Slovak Institute for Cardiovascular Diseases Košice Slovakia
Department of Critical Care East Slovak Institute for Cardiovascular Diseases Košice Slovakia
Department of Critical Care National Institute of Cardiovascular Diseases Bratislava Slovakia
Department of Pathology Charles University Faculty of Medicine in Pilsen Czech Republic
Zobrazit více v PubMed
Basso C. Myocarditis. N Engl J Med. 2022;387(16):1488–1500. doi: 10.1056/NEJMra2114478. PubMed DOI
Bracamonte-Baran W, Čiháková D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017;1003:187–221. doi: 10.1007/978-3-319-57613-8_10. PubMed DOI PMC
Dec GW, Fallon JT, Southern JF, Palacios I. “Borderline” myocarditis: an indication for repeat endomyocardial biopsy. J Am Coll Cardiol. 1990;15(2):283–289. doi: 10.1016/s0735-1097(10)80050-6. PubMed DOI
Caforio ALP, Pankuweit S, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648. doi: 10.1093/eurheartj/eht210. 2648a-2648d. PubMed DOI
Kociol RD, Cooper LT, Fang JC, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141(6):e69–e92. doi: 10.1161/CIR.0000000000000745. PubMed DOI
Li S, Xu S, Li C, et al. A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study. Sci China Life Sci. 2019;62(3):369–380. doi: 10.1007/s11427-018-9501-9. PubMed DOI
Winter MP, Sulzgruber P, Koller L, Bartko P, Goliasch G, Niessner A. Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. Heart Fail Rev. 2018;23(4):573–581. doi: 10.1007/s10741-018-9709-9. PubMed DOI PMC
Kruse RL, Albayda J, Vozniak SO, et al. Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. J Clin Apher. 2022;37(3):253–262. doi: 10.1002/jca.21968. PubMed DOI PMC
Liu L, Dong Y, Gao H, et al. Cardiogenic shock as the initial manifestation of systemic lupus erythematosus. ESC Heart Fail. 2020;7(4):1992–1996. doi: 10.1002/ehf2.12806. PubMed DOI PMC
Sogbe M, Blanco-Di Matteo A, Di Frisco IM, Bastidas JF, Salterain N, Gavira JJ. Systemic lupus erythematosus myocarditis after COVID-19 vaccination. Reumatol Clin. 2023;19(2):114–116. doi: 10.1016/j.reuma.2022.06.003. PubMed DOI PMC
Baritussio A, Schiavo A, Basso C, et al. Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. Eur J Heart Fail. 2022;24(6):1033–1044. doi: 10.1002/ejhf.2496. PubMed DOI
Chapa JJ, Ilonze OJ, Guglin ME, Rao RA. Heart transplantation in systemic lupus erythematosus: a case report and meta-analysis. Heart Lung. 2022;52:174–181. doi: 10.1016/j.hrtlng.2022.01.003. PubMed DOI
Afzal A, Higgins RS, Philbin EF. Heart transplant for dilated cardiomyopathy associated with polymyositis. Heart. 1999;82(4):e4. doi: 10.1136/hrt.82.4.e4. PubMed DOI PMC
